期刊文献+

髂内动脉介入术前化疗治疗浸润性膀胱癌临床疗效 被引量:4

Clinical Efficacy of Invasive Bladder Cancer with Preoperative Interventional Chemotherapy through Iliac Artery
下载PDF
导出
摘要 目的 探索髂内动脉介入术前化疗治疗浸润性膀胱癌的疗效和安全性.方法 2007年1月~2013年5月对24例膀胱癌(T2N0M0)术前行顺铂、丝裂霉素髂内动脉灌注化疗,2~3 h后对经尿道膀胱肿瘤电切术后行常规膀胱灌注化疗.结果 24例患者髂内动脉介入化疗均成功,术后不良反应包括发热 10 例(41.67%),恶心、呕吐5例(20.8%),厌食、纳差、上腹部不适13例(54.22%),穿刺点血肿1例(4.17%).所有患者在髂内动脉介入化疗后均获得了TUR-Bt机会.经髂内动脉介入化疗后完全缓解0例(0%),部分缓解22 例(91.67%),病情稳定2 例(8.33%).全部病例随访3~18 个月,平均8个月,死亡0例,复发3例.结论 经髂内动脉灌注化疗治疗浸润性膀胱癌安全有效,能明显提高疗效,是浸润性膀胱癌安全有效的姑息性治疗方法.
出处 《河南科技大学学报(医学版)》 2014年第1期30-31,共2页 Journal of Henan University of Science & Technology:Medical Science
  • 相关文献

参考文献5

  • 1Tsukamoto S,Ishikawa S,Tsutsumi M,et al.An organ-sparing treatment using intra-arterial chemotherapy and radiotherapy for muscle invading bladder carcinoma[J].Scand J Urol Nephrol,2002,36(5):339-343.
  • 2Mitsumori K,Sato K,Kato T,et al.Intra-arterial chemotherapy in urological cancer[J].Gan To Kagaku Ryoho,2002,29(2):197-203.
  • 3李鸣,李宁忱,黄真,那彦群.浸润性膀胱癌术前选择性髂内动脉灌注化疗的近远期疗效观察[J].中华泌尿外科杂志,2004,25(10):662-664. 被引量:20
  • 4Belliveau JF,Posner MR,Ferrari L,et al.Cisplatin administered as a continuous 5-day infusion:plasma platinuous levels and urine platinum excretion[J].Cancer Treat Rep,1986,70(10):1215-1217.
  • 5Shipley WU,Kaufman DS,Lane SC,et al.Selective bladder preservation by combined modality protocol treatment:long-term outcomes of 190 patients with invasive bladder cancer[J].Urology,2002,60(1):62-67.

二级参考文献7

  • 1Tsukamoto S, Ishikawa S, Tsutsumi M, et al. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma. Scand J U rol Nephrol,2002,36:339-343.
  • 2Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer:long-term results. J Clin Oncol,2002,20: 3061-3071.
  • 3Hayashi N,Arima K, Kawamura J,et al. Preoperative balloon occluded arterial infusion chemotherapy for locally invasive bladder cancer-accurate staging for bladder preservation. Hinyokika Kiyo, 1999,45:139-143.
  • 4Startsev VY. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences. Arch Ital Urol Androl,2002,74:54-56.
  • 5Kobayashi M,Sugaya Y,Yuzawa M,et al. Intra-arterial infusion chemotherapy for superficial bladder cancer. Hinyokika Kiyo, 1999,45:605 -607.
  • 6邓昕,吴永安,姜毅,丛培生,李树伦.浸润性膀胱癌术前超选择性动脉化疗的临床观察[J].中华外科杂志,2000,38(4):278-279. 被引量:14
  • 7黄甫初,王良圣.经动脉灌注区域化疗治疗浸润性膀胱癌[J].国外医学(泌尿系统分册),2000,20(5):226-227. 被引量:17

共引文献19

同被引文献34

  • 1陈嵘,徐月敏,张心如.浸润性膀胱癌根治术后辅助化疗的临床价值[J].同济大学学报(医学版),2007,28(3):100-104. 被引量:1
  • 2AhmedinJemal. Global cancer statistics 2011 [J]. CA Cancer J Clin ,2011,49 :33-64.
  • 3Meeks J,Bellmunt J, Boehner B, et al. A systematic re-view of neoadjuvant chemotherapy for musele-invasive bladder eaneer[J]. Eur Urol, 2012,62 (3) : 523-533.
  • 4Winquiste E, Kirchner T, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the blad- der : asystemtic review and recta-analysis [J]. J Urol, 2004,171 (2Ptl) : 561-569.
  • 5Alva A,Tallman C, Segal R, et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for musel6-invasive bladder cancer, a mu|tidisciplinary ap- proach [J]. Cancer ,2012,118(1) :44-53.
  • 6Grif~iths G, Hall R, Sylvester R, et al. International phase [I trial assessing neoadjuvant cisplatin, methotrex- ate and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA063094 trial [J]. J Clin Oncal,2011,349(9) :2171-2177.
  • 7Von D,Hansen S, Roberts M, et al. Gemeitabine and cisplatin versus methotrexate, vinblastine, doxorubine, and cisplatin in advanced or metastatic bladder cancer Results of a large randomized multicenter , multinational multicenter, phase llI study [J]. J Clin Oncol, 2000, 18(17) :3068-3077.
  • 8何景盛,王涛,也学衡,等.术前新辅助化疗治疗浸润性膀胱癌的临床疗效分析[J].医药前沿,2012,4:113-114.
  • 9Solsona E,Iborra L, Ricos J, et al. Feasibility of transure- thral resection for muscle infiltrating carcinoma of the blad der~long-term follow-up of a prospective study[J]. J Urol, 1998,159:95-98.
  • 10Thissen A,Pfister D, Heidenreich A, et al. Muscle in vasive bladder cancer after radical cystectomy. Prognos- tic factors of adjuvant chemotherapyl-J~. Urologe A, 2013,52 (9) : 1233-1241.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部